Abstract:Bcl-xL, a member of Bcl-2 protein family functioned as dominant regulators of apoptotic cell death, has been reported to play important roles in malignant transformation and tumor development. In the present study, our aim was to explore the roles of Bcl-xL overexpression and determine its possibility as a therapeutic target in human osteosarcoma. Real-time quantitative RT-PCR and Western blot or immunohistochemistry assays were performed to detect the expression of Bcl-xL mRNA and protein in human osteosarcoma cell lines or tissue samples. The expression of other Bcl-2 family proteins (Bcl-2, Mcl-1, Bim and Bik) in osteosarcoma tissues was also detected by immunohistochemistry. The associations of Bcl-xL mRNA expression with clinicopathologic factors and prognosis of osteosarcoma patients were evaluated. RNA interference or gene overexpression technologies were employed to downregulate or upregulate endogenous Bcl-xL expression in osteosarcoma cells and the effects of Bcl-xL downregulation or upregulation on phenotypes and chemo- or radiosensitivity of human osteosarcoma cells were analyzed. Finally, the mechanism of synergistic effects of Bcl-xL downregulation and chemo- or radiotherapy was explored by detecting the activity of caspase-3. The expression levels of Bcl-xL mRNA and protein in high metastatic osteosarcoma cells showed higher than those in low metastatic osteosarcoma cells. Moreover, the levels of Bcl-xL mRNA expression were significantly higher in osteosarcoma tissues than those in chondroma or corresponding non-tumor tissues (P<0.01), and osteosarcoma tissues showed stronger immunostaining of Bcl-xL protein than non-tumor tissues. The stronger staining of Bcl-2 and Mcl-1 proteins was also observed, while the staining of pro-apoptotic proteins (Bim and Bik) was significantly weaker or not detected in osteosarcoma tissues. The higher levels of Bcl-xL mRNA expression were significantly correlated with advanced clinical stage (P=0.005) or hematogenous metastasis (P=0.001) of osteosarcoma patients. Osteosarcoma patients with higher Bcl-xL mRNA expression showed a poorer survival compared with those with lower expression (P=0.039). Bcl-xL downregulation or upregulation could significantly reduce or increase the proliferation capacity of osteosarcoma cells. Furthermore, Bcl-xL downregulation could significantly enhance in vitro chemo- or radiosensitivity of osteosarcoma cells, which might be associated with elevated activity of caspase-3. Taken together, overexpression of Bcl-xL may play important roles in osteosarcoma progression and this molecule will be a potential chemo- or radiotherapeutic molecular target for osteosarcoma therapy.

Downregulation of BZW2 Inhibits Osteosarcoma Cell Growth by Inactivating the Akt/mTOR Signaling Pathway.

Zinc finger Asp-His-His-Cys palmitoyl -acyltransferase 19 accelerates tumor progression through wnt/β-catenin pathway and is upregulated by miR-940 in osteosarcoma

Knockdown of WWP1 Inhibits Growth and Invasion, but Induces Apoptosis of Osteosarcoma Cells.

BZW2 promotes the malignant progression of colorectal cancer via activating the ERK/MAPK pathway

Promotion of Proliferation and Inhibition of Apoptosis by Diacylglycerol Kinase Zeta, a Potential Oncogene of Osteosarcoma

Silencing of cytoskeleton-associated protein 2 represses cell proliferation and induces cell cycle arrest and cell apoptosis in osteosarcoma cells.

Down-regulation of RPS9 Inhibits Osteosarcoma Cell Growth through Inactivation of MAPK Signaling Pathway

Inhibition of BUB1 suppresses tumorigenesis of osteosarcoma via blocking of PI3K/Akt and ERK pathways

BTG2 Inhibits the Proliferation and Metastasis of Osteosarcoma Cells by Suppressing the PI3K/AKT Pathway.

Decreased WWOX Expression Promotes Angiogenesis in Osteosarcoma.

DownRegulated SOX4 Expression Suppresses Cell Proliferation, Migration, and Induces Apoptosis in Osteosarcoma In Vitro and In Vivo

Functional and biological analysis of Bcl-xL expression in human osteosarcoma.

Low Expression of ZFP36L1 in Osteosarcoma Promotes Lung Metastasis by Inhibiting the SDC4-TGF-β Signaling Feedback Loop

DGKZ Acts As a Potential Oncogene in Osteosarcoma Proliferation Through Its Possible Interaction with ERK1/2 and MYC Pathway

BZW2 promotes malignant progression in lung adenocarcinoma through enhancing the ubiquitination and degradation of GSK3β

Targeting the Wnt/β-catenin pathway in human osteosarcoma cells

Proanthocyanidin B2 Inhibits Proliferation and Induces Apoptosis of Osteosarcoma Cells by Suppressing the PI3K/AKT Pathway

miRNA-449a is downregulated in osteosarcoma and promotes cell apoptosis by targeting BCL2

Aberrant Activation of Wnt/β-catenin Signaling Drives Proliferation of Bone Sarcoma Cells.

Downregulation of Cdc6 Inhibits Tumorigenesis of Osteosarcoma in Vivo and in Vitro.

TBL 1 XR 1 promotes migration and invasion in osteosarcoma cells and is negatively regulated by miR-1865 p